Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Epigenetics World Congress

Aldo Roccaro's Biography



Aldo Roccaro, Senior Scientist, Dana Farber Cancer Institute

Aldo M. Roccaro, M.D., Ph.D. is a Senior Scientist, at Harvard Medical School, Boston, MA. He completed his M.D. degree at Bari Medical School, Bari, Italy, and joined the Dana-Farber Cancer Institute as postdoctoral fellow in 2004. Prior to this, he was fellow in Hematology/Oncology at the University of Bari, Bari, Italy; and at the Unit of Blood Diseases and Cell Therapies, University of Brescia Medical School, Brescia, Italy. Dr. Roccaro’s research mainly focuses on B cell malignancies. Specific areas of interests are neoangiogensis in Multiple Myeloma (MM) and Waldenstrom’s Macroglobulinemia (WM). He has been recently pioneering work on microRNAs in WM and MM, contributing to major advances in understanding the role of epigenetic modification that lead to the initiation and progression of MM and WM. Dr. Roccaro is recipient of several Awards (Italian Association for Cancer Research, Berlucchi Foundation, ASH, EHA, The Doctors’ Cancer Foundation, Claudia Adams Barr, Accademia Nazionale dei Lincei). Under the mentorship of extremely well know experts in the field of WM and MM (Drs. F. Dammacco, A. Vacca, K.C. Anderson, I.M. Ghobrial, S.P. Treon), he has authored more than 90 manuscripts in peer-reviewed literature and has written nine books chapters in hematology/oncology textbooks. He also contributed to the English to Italian translation of the “Netter’s Clinical Anatomy”.

Aldo Roccaro Image

miRNA Modifications Play a Pivotal Role in B-cell Malignancies

Wednesday, 27 April 2011 at 16:00

Add to Calendar ▼2011-04-27 16:00:002011-04-27 17:00:00Europe/LondonmiRNA Modifications Play a Pivotal Role in B-cell MalignanciesEpigenetics World Congress in BostonBostonSELECTBIOenquiries@selectbiosciences.com

Epigenetic modifications play a pivotal role in the pathogenesis of hematologic malignancies, including Waldesntrom’s Macroglobulinemia (WM) and Multiple Myeloma (MM). MicroRNA (miRNA) expression profiling of primary WM and MM tumor cells has demonstrated a clear miRNA signature in these B-cell malignancies. Moreover, functional studies have revealed the crucial role of miRNA-155 and miRNA-15a/16-1 in regulating the biology of WM and MM, respectively, thus providing the rational for using miRNA-based therapeutic strategies in these diseases.


Add to Calendar ▼2011-04-26 00:00:002011-04-27 00:00:00Europe/LondonEpigenetics World CongressEpigenetics World Congress in BostonBostonSELECTBIOenquiries@selectbiosciences.com